For 7% of women presenting a bipolar disorder (BD), their rst episode occurred in the context of the perinatal period (Viguera et al. 2011). In women with bipolar disorder prior to pregnancy, the risk of relapse may reach up to 20% during preg­nancy (Van der Lugt etal. 2012) and is between 50% and 70% post-partum (Jones and Craddock 2005; Viguera etal. 2011). Conversely, bipolar disorders themselves seem to have a possible inuence on the course of pregnancy: the review of Mohamed etal. (2023) suggests that the risk of obstetric complications would be higher in bipolar patients—treated or not—than in the general population. The recent work of Chan etal. (2024) is along the same lines, nding that in a popula­tion-based cohort of 465,069 women—including 302 women with a diagnosis of BD, of whom 168 had one or more prescriptions for mood stabilizers during preg­nancy (treated BD) and 134 were not exposed to mood stabilizers during pregnancy (untreated BD)—BD was signicantly associated with an increased risk of gesta­tional diabetes (ORa: 1.75 [95% CI: 1.15–2.70]) and maternal somatic hospitaliza­tion ≤90 days after discharge from the index delivery (2.12 [1.19–3.90]); in treatment status-stratied analyses, treated BD women had a signicantly increased